Trials / Completed
CompletedNCT00509769
A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
A Phase II, Single-arm, Open-label Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed While Receiving HER2-Directed Therapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 112 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This was a multi-institutional, open-label, single-arm, Phase II study of trastuzumab emtansine (T-DM1) administered by intravenous (IV) infusion to patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Trastuzumab emtansine [Kadcyla] | Trastuzumab emtansine was provided in either a liquid or a lyophilized formulation. |
Timeline
- Start date
- 2007-07-01
- Primary completion
- 2009-01-01
- Completion
- 2009-06-01
- First posted
- 2007-07-31
- Last updated
- 2013-04-02
- Results posted
- 2013-04-02
Locations
40 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00509769. Inclusion in this directory is not an endorsement.